Clinical Research Trials: Cost, Efficiency and Effectiveness Introduction The monitoring of the U.S. segment of the upcoming clinical trials can be achieved using one of three monitoring models: A) Sponsor In-House (SIH) monitoring, B) Outsourced monitoring through a Clinical Research Organization (CRO), or C) Independent Clinical Research Assistant (ICRA). Each of the three monitoring options offer advantages and disadvantages that must be considered to choose the most effective one to accomplish the research goals. Ideally a comparison should be made between bids, as well as assessing the financial stability of the organizations, and the structuring of the contracts (Fletcher and Edwards, 2007, p501). To give the three options fair...The end:
.....tion and certification, and a high overall rating of 37. These factors combine show this model to be of good value and high likelihood of accomplishing research goals with efficiency and accuracy. Works Cited Eisenstein, E., Collins, R., Cracknell , B., Podesta , O., et. al. (2007). Sensible approaches for reducing clinical trial costs. Clinical Trials, 5(1): 75 – 84. Fletcher, A. and Edwards, L. (2002). Principles and practice of pharmaceutical medicine. San Francisco: Wiley. Kulakowski , E. and Chronister , L. (2006). Research administration and management. Boston: Jones and Bartlett. Wailoo , A., Roberts, J., Brazier, J. and McCabe, C. (2007). Efficiency, equity and NICE clinical guidelines. British Medical Journal, 328(7439): 536 – 537.